Trial Profile
Prospective, Open-Label, Multi-Center, Phase III CLinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Surgical Procedures
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Surgical blood loss; Von Willebrand disease
- Focus Therapeutic Use
- Acronyms WONDERS
- Sponsors Octapharma
- 17 Apr 2017 Status changed from recruiting to discontinued, as the trial met its primary endpoint at the pre-specified interim analysis after 30 surgical procedures, according to the results published in the Haemophilia
- 01 Mar 2017 Primary endpoint (Overall hemostatic efficacy (success or failure) of wilate, based on the intra-operative assessment of the surgeon and the post-operative assessment by the investigator using a 4-point ordinal efficacy scale) has been met, according to the results published in the Haemophilia
- 01 Mar 2017 Results published in the Haemophilia